Nasdaq 100 52-Week Highs & Lows Radar: AMGEN (AMGN), Applovin (APP) and more
MarketsFN Team
Screening all 101 Nasdaq 100 constituents for stocks nearest to their 52-week high and their 52-week low. Data as of October 30, 2026. % Realized = 52-week total return.
Legend: RSI > 70 = overbought · RSI < 30 = oversold · Green % Realized = positive 52W return · Red = negative.
📈 Nearest to 52-Week High
Sectors represented: Healthcare (3), Technology (1), Consumer Defensive (1)
| Ticker | Company | Sector | Price Last | % Realized | 52-Week High Date | RSI | % above MA200 | Trend |
|---|---|---|---|---|---|---|---|---|
| AMGN | AMGEN Inc | Healthcare | $470.42 | +61.10% | 2026-10-30 | 72.8 | +25.5% | Above MA20, MA50, MA200 |
| GILD | Gilead Sciences, Inc | Healthcare | $172.39 | +45.55% | 2026-10-30 | 75.5 | +23.2% | Above MA20, MA50, MA200 |
| REGN | Regeneron Pharmaceuticals, Inc | Healthcare | $916.24 | +40.09% | 2026-10-30 | 78.0 | +24.2% | Above MA20, MA50, MA200 |
| ROP | Roper Technologies Inc | Technology | $464.51 | +4.76% | 2026-10-30 | 81.8 | +27.3% | Above MA20, MA50, MA200 |
| KDP | Keurig Dr Pepper Inc | Consumer Defensive | $35.74 | +29.14% | 2026-10-30 | 70.6 | +19.1% | Above MA20, MA50, MA200 |
AMGN | AMGEN Inc | Healthcare | Price Last: $470.42 | % Realized: +61.10% | RSI: 72.8 | % above MA200: +25.5% | Trend: Above MA20, MA50, MA200
Amgen develops biologic medicines for serious illnesses, including top-selling drugs like Enbrel and Prolia. Investors care because its high-margin therapies face patent cliffs, making pipeline execution critical as it expands into obesity drugs to offset biosimilar competition.
AMGN shows strong momentum with bullish MA alignment (price > MA20 > MA50 > MA200) and overbought RSI(14) at 72.8. At its 52-week high after a 61.1% rally, this suggests extended upside but warrants caution near resistance.
GILD | Gilead Sciences, Inc | Healthcare | Price Last: $172.39 | % Realized: +45.55% | RSI: 75.5 | % above MA200: +23.2% | Trend: Above MA20, MA50, MA200
Gilead Sciences is a biopharma leader in HIV, hepatitis C, and oncology treatments, including blockbuster antiviral drugs. Investors care because its pipeline addresses high-need therapeutic areas with durable revenue potential, though patent cliffs require careful monitoring.
Technically bullish with RSI(14) at 75.5 (overbought) and price > MA20 > MA50 > MA200. At 52-week highs (+45.6% YoY), momentum is extreme but may warrant caution near resistance.
REGN | Regeneron Pharmaceuticals, Inc | Healthcare | Price Last: $916.24 | % Realized: +40.09% | RSI: 78.0 | % above MA200: +24.2% | Trend: Above MA20, MA50, MA200
Regeneron Pharmaceuticals develops biologic medicines for eye diseases, asthma, and cancer, with blockbuster drugs like Eylea and Dupixent driving revenue. Investors care because its innovative pipeline and antibody platform could sustain growth beyond current products.
Technically overbought (RSI 78.0) near 52-week highs (+40.1%), with mixed MA alignment (above MA20/MA50/MA200). This suggests extended momentum that may need consolidation.
ROP | Roper Technologies Inc | Technology | Price Last: $464.51 | % Realized: +4.76% | RSI: 81.8 | % above MA200: +27.3% | Trend: Above MA20, MA50, MA200
Roper Technologies acquires and operates niche software and tech-enabled businesses with high recurring revenue, focusing on asset-light models in healthcare, transportation, and energy. Investors care for its consistent cash flow generation and disciplined capital allocation in underpenetrated verticals.
Technically overbought (RSI 81.8) but in strong uptrend (price > MA20 > MA50 > MA200). At 52-week highs, momentum suggests continuation risk/reward favors bulls near-term despite stretched readings.
KDP | Keurig Dr Pepper Inc | Consumer Defensive | Price Last: $35.74 | % Realized: +29.14% | RSI: 70.6 | % above MA200: +19.1% | Trend: Above MA20, MA50, MA200
Keurig Dr Pepper Inc (KDP) manufactures single-serve coffee systems (Keurig) and distributes branded beverages (Dr Pepper, Snapple). Investors care for its dual exposure to at-home coffee consumption and stable CSD/RTD beverage demand, with pricing power in both segments.
Technically bullish: price at 52-week high (0.0% below), RSI(14) at 70.6 (overbought threshold), with confirmed uptrend (price > MA20 > MA50 > MA200). Momentum-driven but extended.
📉 Nearest to 52-Week Low
Sectors represented: Communication Services (4), Consumer Cyclical (1)
| Ticker | Company | Sector | Price Last | % Realized | 52-Week Low Date | RSI | % above MA200 | Trend |
|---|---|---|---|---|---|---|---|---|
| APP | Applovin Corp | Communication Services | $232.65 | -62.51% | 2026-10-30 | 26.1 | -44.1% | Below MA20, MA50, MA200 |
| NFLX | Netflix Inc | Communication Services | $62.61 | -42.51% | 2026-10-28 | 32.7 | -23.3% | Below MA20, MA50, MA200 |
| BKNG | Booking Holdings Inc | Consumer Cyclical | $149.52 | -26.42% | 2026-10-28 | 34.3 | -15.4% | Below MA20, MA50, MA200 |
| TTWO | Take-Two Interactive Software, Inc | Communication Services | $192.22 | -23.96% | 2026-03-27 | 33.3 | -12.6% | Below MA20, MA50, MA200 |
| GOOG | Alphabet Inc | Communication Services | $280.48 | -0.50% | 2026-03-30 | 21.6 | -17.2% | Below MA20, MA50, MA200 |
APP | Applovin Corp | Communication Services | Price Last: $232.65 | % Realized: -62.51% | RSI: 26.1 | % above MA200: -44.1% | Trend: Below MA20, MA50, MA200
Applovin operates a mobile app monetization platform connecting developers with advertisers, leveraging machine learning to optimize ad placements. Investors care for its exposure to mobile gaming growth and programmatic advertising, though recent performance reflects sector-wide digital ad pressures.
Technically dire with RSI(14) at 26.1 (oversold) and bearish MA alignment (price < MA20 < MA50 < MA200). Testing 52-week lows (-62.5% Y/Y) signals severe breakdown risk, not momentum.
NFLX | Netflix Inc | Communication Services | Price Last: $62.61 | % Realized: -42.51% | RSI: 32.7 | % above MA200: -23.3% | Trend: Below MA20, MA50, MA200
Netflix Inc dominates global streaming with 220M+ subscribers, pioneering original content production. Investors watch for pricing power amid competition and free cash flow inflection as growth shifts to international markets.
Netflix tests critical support at 1.0% above 52-week lows with bearish MA alignment (price < MA20 < MA50 < MA200) and oversold RSI(14) at 32.7. The -42.5% annual return signals severe downside momentum, demanding caution until MA structure improves.
BKNG | Booking Holdings Inc | Consumer Cyclical | Price Last: $149.52 | % Realized: -26.42% | RSI: 34.3 | % above MA200: -15.4% | Trend: Below MA20, MA50, MA200
Booking Holdings operates leading online travel platforms (Booking.com, Priceline, Kayak) connecting travelers with lodging/transportation globally. Investors care due to its dominant market position in digital travel bookings, capitalizing on secular growth in online travel adoption despite cyclical sensitivity.
Technically concerning: RSI(14) at 34.3 shows near-oversold conditions, but bearish MA alignment (price < MA20 < MA50 < MA200) confirms sustained downtrend. Stock tests critical support at just 1.1% above 52-week low after 26.4% annual decline.
TTWO | Take-Two Interactive Software, Inc | Communication Services | Price Last: $192.22 | % Realized: -23.96% | RSI: 33.3 | % above MA200: -12.6% | Trend: Below MA20, MA50, MA200
Take-Two Interactive develops and publishes video games through Rockstar Games (Grand Theft Auto, Red Dead Redemption) and 2K (NBA 2K, Borderlands). Investors watch for GTA VI's 2025 release, which could drive record sales given GTA V's 190M+ lifetime units.
Technically distressed: RSI(14) at 33.3 shows oversold conditions amid a sustained downtrend (price < MA20 < MA50 < MA200). The stock tests critical support, trading just 1.3% above 52-week lows after a 24% annual decline. MA alignment signals persistent selling pressure.
GOOG | Alphabet Inc | Communication Services | Price Last: $280.48 | % Realized: -0.50% | RSI: 21.6 | % above MA200: -17.2% | Trend: Below MA20, MA50, MA200
Alphabet Inc (GOOG) dominates global digital advertising through Google Search (91% market share) and YouTube, while its cloud division (Google Cloud) is the third-largest provider. Investors care due to its AI leadership (DeepMind, Gemini), $116B cash position, and 20%+ operating margins in core businesses.
Technically, GOOG shows severe weakness with RSI(14) at 21.6 (oversold) and bearish MA alignment (price < MA20 < MA50 < MA200). Trading just 2.7% above 52-week lows, this signals capitulation, not momentum. The -0.5% annual return underperforms tech peers.
Market Commentary
The clustering of biopharma (AMGN, GILD, REGN) and defensive growth names (ROP, KDP) near 52-week highs suggests a risk-off rotation within tech, with investors favoring stable cash flows and healthcare resilience amid macroeconomic uncertainty. Conversely, ad-tech (APP), streaming (NFLX), and digital travel (BKNG) hovering near lows reflect cyclical pressure on discretionary spending and concerns over digital ad growth.
Sector dispersion highlights macro bifurcation: defensive sectors benefit from Fed tightening and recession hedging, while consumer-facing tech suffers from inflation-driven budget cuts. Alphabet's (GOOG) proximity to lows despite its dominance underscores market skepticism on cloud growth deceleration and regulatory risks, while Take-Two's (TTWO) weakness mirrors gaming sector softness post-pandemic.
Key technical levels loom for NFLX (+1.0% above low) and GOOG (+2.7% above low); breaks below could trigger algorithmic selling. For highs, AMGN and REGN face profit-taking risks at resistance. Catalysts include Q2 earnings revisions, Fed policy clarity, and any inflection in consumer spending data that could reverse the current barbell positioning.
Methodology: All 101 Nasdaq 100 constituents screened. 52-week high = highest daily close over the past 252 trading days (approx. 1 year). 52-week low = lowest daily close over the same period. Distance = (current price / extreme − 1) × 100. Technical indicators computed on up to 1 year of daily OHLCV data.
Disclaimer: For informational purposes only. Not investment advice. Past performance is not indicative of future results.
